- $3.50bn
- $4.39bn
- $1.86bn
Brief: Ashland Completes Sale Of Nutraceuticals Business
U.S. RESEARCH ROUNDUP-Amphastar Pharmaceuticals, Guardant Health, Upwork
Ashland Inc reports results for the quarter ended in January - Earnings Summary
Brief: Ashland Outlook FY Revenue USD 2,100 Million
Ashland Inc expected to post earnings of $1.45 a share - Earnings Preview
U.S. RESEARCH ROUNDUP-AN2 Therapeutics, Ecolab, RPM International
Brief: Ashland Board Appoints Ashish K. Kulkarni As New Director
Brief: Turnspire Capital Partners To Acquire Ashland Nutraceuticals Business
Brief: Ashland Signs Definitive Agreement To Sell Nutraceuticals Business To Turnspire Capital Partners
U.S. RESEARCH ROUNDUP- Mastercard, Metagenomi, Ziff Davis
Brief: Ashland Outlook FY Adjusted EBITDA USD 470-500 Million
Ashland Inc expected to post earnings of $1.14 a share - Earnings Preview
Brief: Ashland Board Appoints Scott A. Tozier As New Director
U.S. RESEARCH ROUNDUP-Ashland, Oportun Financial, Palomar Holdings
U.S. RESEARCH ROUNDUP-AT&T, Lennox International, Mastercard
Ashland Inc reports results for the quarter ended in December - Earnings Summary
Brief: Ashland Outlook FY Adjusted EBITDA USD 460-500 Million
Ashland Inc expected to post earnings of 19 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Caredx, Ebix, Vera Therapeutics